Navigating Post-Afatinib Progression: Treatment Sequencing Strategies in NSCLC
December 20th 2023
Expert insights on sequencing treatment options for patients with uncommon EGFR mutations who have progressed on afatinib, emphasizing clinical trial considerations, biomarker testing, and emerging therapeutic approaches.